Efficacy of Tiotropium bromide (Spiriva 2.5 microgram Respimat 60 puffs) for chronic asthmatic cough refractory to intensive therapies

Trial Profile

Efficacy of Tiotropium bromide (Spiriva 2.5 microgram Respimat 60 puffs) for chronic asthmatic cough refractory to intensive therapies

Recruiting
Phase of Trial: Phase II

Latest Information Update: 22 Sep 2016

At a glance

  • Drugs Tiotropium bromide (Primary)
  • Indications Asthma
  • Focus Therapeutic Use
  • Most Recent Events

    • 13 Sep 2016 Status changed from not yet recruiting to recruiting.
    • 31 May 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top